IRIS
BONIFACINO, TIZIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.456
Totale 8.456
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 8.456
Totale 8.456
Salva come PNG Salva come JPEG
Città #
Genova 6.178
Rapallo 1.170
Genoa 1.074
Bordighera 34
Totale 8.456
Salva come PNG Salva come JPEG
Nome #
In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1G93A mouse model of amyotrophic lateral sclerosis. 155
Acute stress increases depolarization-evoked glutamate release and presynaptic SNARE complex accumulation in prefrontal/frontal cortex. The dampening action of antidepressants. 153
Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways 150
In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis 144
Genetic inactivation of mGlu5 receptor improves motor coordination in the Grm1crv4 mouse model of SCAR13 ataxia 141
Characterization of the Mitochondrial Aerobic Metabolism in the Pre- and Perisynaptic Districts of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis 137
Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the disease 135
Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: a mechanism for the excessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis. 129
Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes 125
Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine 125
Altered Mechanisms Underlying the Abnormal Glutamate Release in Amyotrophic Lateral Sclerosis at a Pre-Symptomatic Stage of the Disease. 120
The endocannabinoid system in rat gliosomes and its role in the modulation of glutamate release 118
Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down Syndrome. 117
Colocalization of neurotransmitter transporters on the plasma membrane of the same nerve terminal may reflect cotransmission. 117
Enriched experience and recovery from amblyopia in adult rats: impact of motor, social and sensory components. 115
Group I metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis 114
Acute stress rapidly increases the readily releasable pool of glutamate vesicles in prefrontal and frontal cortex through non-genomic action of corticosterone 113
Role of calpain-1 in the early phase of experimental ALS 109
Differential expression of metabotropic glutamate and GABA receptors at neocortical glutamatergic and GABAergic axon terminals 106
Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis 106
Stress and corticosterone increase the readily releasable pool of glutamate vesicles in synaptic terminals of prefrontal and frontal cortex 101
Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis 99
Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. 98
Glutamate release from astrocytic gliosomes under physiological and pathological conditions 95
Increased [3H]D-aspartate release and changes in glutamate receptor expression in the hippocampus of the mnd mouse. 95
Ketamine modulates glutamate release, BDNF trafficking and dendrite morphology in rats vulnerable to chronic mild stress 95
Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression 95
Knocking-down mGluR1 and mGluR5 in the SOD1/G93A mouse model of amyotrophic lateral sclerosis ameliorates survival and disease progression 93
Fluoxetine treatment promotes functional recovery in a rat model of cervical spinal cord injury 92
Intravenous mesenchymal stem cells improve survival and motor functions in symptomatic mutant SOD1/G93A mice 92
Acute stress rapidly increases the readily releasable pool of glutamate vesicles in prefrontal and frontal cortex through non-genomic action of corticosterone. 91
Abnormal and precocious exocytotic glutamate release in a mouse model of amyotrophic lateral sclerosis 90
Synaptic mechanisms underlying the excessive and precocious glutamate release in the spinal cord of sod1g93a mice. 90
GroupI metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis 89
mGluR1 and mGluR5 knock-down improves survival, motor skills and disease progression in amyotrophic lateral sclerosis mouse model 89
Knocking-down mGlu1 receptors prolongs survival and ameliorates disease progression in the SOD1/G93A mouse model of ALS. 88
Metabotropic glutamate receptor 5 as a potential target in ALS 88
Altered glucose catabolism in the presynaptic and perisynaptic compartments of SOD1G93A mouse spinal cord and motor cortex indicates that mitochondria are the site of bioenergetic imbalance in ALS 85
Targeting Group I Metabotropic Glutamate Receptors in Amyotrophic Lateral Sclerosis 84
Acute stress and corticosterone increase the readily releasable pool of glutamatergic vesicles in rat synaptosomes of prefrontal/frontal cortex via mineralocorticoid and glucocorticoid receptors 84
Intravenous Mesenchymal Stem Cells Improve Survival and Motor Function in Experimental Amyotrophic Lateral Sclerosis 83
GROUP I METABOTROPIC GLUTAMATE RECEPTORS AND NEUROTOXICITY IN AMYOTROPHIC LATERAL SCLEROSIS 79
Acute ketamine restores deficits in glutamate release and related molecular mechanisms induced by chronic mild stress in vulnerable rats 79
Abnormal glutamate release in a mouse model of amyotrophic lateral sclerosis 77
Ketamine restores changes in glutamate release, dendrite morphology and BDNF trafficking in the hippocampus of rats vulnerable to chronic mild stress 77
Targeting group i metabotropic glutamate receptors in experimental als. 77
Group I metabotropic glutamate receptors tune excitotoxicity in amyotrophic lateral sclerosis 76
Effect of miRNAs shuttled by exosomes derived from primed-MSCs on activated-microglia phenotype and possible implication in amyotrophic lateral sclerosis. 76
Abnormal glutamate release in a mouse model of amyotrophic lateral sclerosis 75
Reducing the expression of mGlu1 and mGlu5 receptors ameliorates survival and disease progression in SOD1G93A mice 75
miRNAs shuttled by exosomes derived from primed-MSCs affect the activated-microglia phenotype and possibly support the therapeutic effects of MSC administration in SOD1G93A mice 75
Excessive glutamate release and undelying synaptic mechanisms in a mouse model of amyotrophic lateral sclerosis 75
GLUTAMATE NEUROTRANSMISSION IS MODIFIED IN THE SOD1/G93A MOUSE MODEL OF ALS 74
Astrocyte contribution to the excessive glutamate release in the spinal cord of the SOD1G93A mouse model of amyotrophic lateral sclerosis 74
Amyotrophic lateral sclerosis and excitotoxicity: role of Group I metabotropic glutamate receptors 72
Knocking down mglu1 receptors prolongs survival and improves symptomatology in a mouse model of amyotrophic lateral sclerosis 72
The Modulation of Glutamate Release by Group I Metabotropic Glutamate Auto-Receptors in ALS 71
Reducing excitotoxicity knocking down mGluR1: prolonged survival and improved symptomatology of SOD1/G93A mouse model of ALS 69
Non conventional activity of the endocannabinoid system at glutamate release in rat cortical astrocytes 69
Neuroprotective Effect of AM404 Against NMDA-Induced Hippocampal Excitotoxicity 69
G93A mutated SOD1-linked murine ALS produces abnormal exocytotic release of glutamate 68
Group I metabotropic glutamate receptors in ALS: knocking-down mGlu1 receptors ameliorates survival and disease progression in SOD1/G93A mice. 68
Partial deletion of mGluR1 receptors prolongs life span and ameliorates motor skills and biochemical and cellular parameters in a mouse model of experimental ALS 67
Mesemchymal stem cells systemically administered in symptomatic mutant SOD1-G93A mice ameliorate survival and motor abilities 67
Altered synaptic mechanisms and excessive glutamate release in amyotrophic lateral sclerosis 67
In-vitro activation of GAT1 transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOd1/G93A(+) mouse model of amyotrophioc lateral sclerosis. 65
Acute stress rapidly increases the readily releasable pool of glutamate vesicles in prefrontal and frontal cortex through corticosterone non-genomic action 64
Altered expression of the GPR17 receptor in the spinal cord of SOD1G93A mice, a model of amyotrophic lateral sclerosis 64
Abnormal Upregulation of GPR17 Receptor Contributes to Oligodendrocyte Dysfunction in SOD1 G93A Mice 63
In vitro Evidence of Abnormal Glutamate to Glutamine Conversion in Astrocytes harvested from a Mouse Model of Amyotrophic Lateral Sclerosis: a potential Experimental Application of N-13-ammonia 63
Group I metabotropic glutamate receptors modulate glutamate exocytosis in a mouse model of als 62
Group I metabotropic glutamate receptors induce excessive glutamate release in the spinal cord of sod1g93a mice 62
Genetic and pharmacological effects of mGlu5 receptor blockade in the SOD1G93A mouse model of amyotrophic lateral sclerosis 62
Intravenous mesenchymal stem cells administration induces survival and symptom amelioration in mutant SOD1 G93A mice 62
Alterations of Synaptic Mechanisms and Excessive Glutamate Release in the Spinal Cord of SOD1G93A Mice 62
Group I metabotropic glutamate receptors in ALS: mGluR1 and mGluR5 autoreceptors induce excessive glutamate release in SOD1/G93A mice. 61
Knocking-down mGluR1 and mGluR5 in the SOD1/G93A mouse model of amyotrophic lateral sclerosis ameliorates survival and disease progression 59
The modulation of Glutamate release by Group I metabotropic Glutamate auto-receptors in ALS 59
The modulation of Glutamate release by pre-synaptic Group I metabotropic Glutamate receptors in ALS 58
Intravenous mesenchymal stem cells administration induces survival and symptom amelioration in mutant SOD1 G93A mice 58
Inactivation of the Grm5 gene improves motor coordination defects in the Grm1crv4 mouse model of SCAR13 ataxia 57
Altered Mechanisms Underlying the Abnormal Glutamate Release in Amyotrophic Lateral Sclerosisat a Pre-Symptomatic Stage of the Disease. 57
Synaptic mechanisms underlying the excessive and precocious glutamate release in the spinal cord of SOD1G93A experimental mice 56
Acute stress increases the readily releasable pool of glutamate vesicles in cortical areas 56
Effects of BND-11624 at ionotropic and metabotropic glutamatergic receptors regulating neurotransmitter release in the rat CNS 55
Knocking-down Group I metabotropic glutamate receptors ameliorates survival and disease progression in SOD1G93A mice. 54
Abnormal glutamate release induced by group I metabotropic glutamate receptors in experimental ALS. 54
Genetic and pharmacological effects by blocking mGlu5 Receptor in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis 54
Genetic inactivation of metabotropic glutamate 5 (mGlu5) receptor ameliorates motor coordination in the Grm1crv4 mouse model of SCAR13 ataxia 53
Molecular mechanism underlying excessive and precocious glutamate release in the spinal cord of the SOD1G93A mouse model of amyotrophic lateral sclerosis. 52
Intravenously administered mesenchymal stem cells improve lifespan and motor skills in a mouse model of ALS. 52
Molecular mechanisms supporting abnormal glutamate release in the spinal cord of a mouse model of Amyotrophic Lateral Sclerosis. 52
Alterations of Synaptic Mechanisms and Excessive Glutamate Release in the Spinal Cord of SOD1G93A Mice 52
Synaptic mechanisms of the abnormal release of glutamate in the spinal cord of pre-symptomatic SOD1G93A mice 50
Reducing mglur5 expression attenuates the reactive phenotype of astrocytes cultured from the spinal cord of late symptomatic SOD1G93A mice 50
Mechanisms underlying the predictive power of high skeletal muscle uptake of FDG in amyotrophic lateral sclerosis 49
Synaptic Mechanisms Sustaining The Excessive And Precocious Glutamate Release In The Spinal Cord Of SOD1G93A Mice 48
Knocking-down mGluR1 and mGluR5 in SOD1G93A mice ameliorates survival and disease progression 48
Sytemic administration of nt-1640 improves survival and motor function in the SOD1/G93A mouse model of ALS. 47
Abnormal and precocious exocytotic release of glutamate in the spinal cord of a mouse model of amyotrophic lateral sclerosis. 46
Totale 8.159
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.252
article - articoli 12.178
book - libri 311
conference - conferenze 12.763
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.504
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019302 0 0 0 0 0 0 0 0 0 0 175 127
2019/20202.130 79 55 82 96 139 253 324 128 173 450 272 79
2020/2021771 46 85 65 41 59 64 67 89 63 66 56 70
2021/20221.332 21 85 62 127 50 107 83 322 84 126 68 197
2022/20231.440 137 147 21 164 212 201 15 104 214 12 183 30
2023/2024888 36 124 33 135 80 235 95 43 46 61 0 0
Totale 8.945